In human viral diseases, misbehaviour of the cellular machinery utilizing ubiquitin is frequently observed. Ubiquitin is a small protein that attaches to target proteins in human cells and signals for their destruction. Human deubiquitinases are enzymes that remove ubiquitin to keep protein levels in balance. Viral pathogens have evolved proteins that mimic human deubiquitinases to evade the immune system by interfering with host ubiquitin-dependent processes.
"Parkinsons disease (PD) is a neurodegenerative disorder that affects approximately 1.5% of the global population over age 65. Current therapeutic interventions for PD are typically limited to attempts to correct the depletion of dopamine once motor symptoms become moderate to severe. Interventions with the potential to improve the cognitive function and quality of life of Parkinsons patients by modulating non-motor symptoms, as well as interventions with the potential to slow the rate of loss of dopaminergic neurons and to delay symptom emergence remain an unmet need.
Bones undergo a renewal process by replenishing calcium mineral through a cellular process known as remodeling. Usually, it happens in a balanced manner, but in many bone diseases, the remodeling process is increased with regional bone metabolism. Bisphosphonate (BP) drugs selectivity and strongly bind to bone mineral and become incorporated at active sites of bone turnover in an increased amount.
Natures ability to convert solar energy to chemical energy in photosynthesis has inspired the development of a host of photoredox systems in efforts to mimic this process. The capacity of fluorine atoms to engender a variety of useful properties in pharmaceuticals, agrochemicals, and performance materials has driven significant research efforts toward the invention of novel fluorination reactions. We
proposed to construct C-F bonds by photoreodox catalysis via a radical pathway. Our project will bring potential benefit to academia and industry.
The ability to repair or regenerate damaged heart presents a major challenge in the treatment of cardiovascular diseases. Current treatments are unsuccessful to regenerate dead myocardium and fail to address the challenge caused by the early loss of cardiac cells. The use of a new drug to stimulate protection of the heart during an ongoing myocardial infarct would be very relevant to the clinical setting, to help patients suffering from heart attack.
Cancer cells are known for their unique capacity to survive and grow in a low oxygen tension environment in the middle of a poorly vascularized solid tumor. This adaptation, which is central to the tumorigenesis process, is mediated by precise cellular mechanisms allowing the regulation of gene expression. Thus, the development of small molecules to modulate the activity of transcription factors is of great therapeutic interest. In order to develop such molecules, we plan to finance, with the help of IntelliSyn Pharma and Mitacs, one M.Sc. student.
This project intends to research vaccine manufacturing process from a broader perspective and apply Quality by Design (QbD) concepts to develop a robust novel process for commercial vaccine production. To implement QbD principles, the impact of several process parameters (including cell density, pH, temperature, and harvest time) on the Critical Quality Attributes (CQAs) of the vaccine product (including yield, potency, and purity) will be revealed using statistical process analytical technologies such as Profiling, Principal Component Analysis, and Monte Carlo simulations.
Coatings are an essential part in the formulation of drug tablets/beads in the pharmaceutical industry. Most film coatings are applied as aqueous or organic-based polymer solution, which cause many issues such as toxicity, high environmental impact, and high operational cost. The goal of this project is to develop a novel coating technology using dry powder. The new coating applications can overcome the disadvantages associated with the traditional use of organic or aqueous solvents.
For the majority of people, weight training builds skeletal muscle, which results in health benefits (e.g., improved disease risk and lifespan). However, despite training, some individuals have trouble gaining muscle (nonresponders). This lack of a response is likely related to an impaired ability to make new proteins (impaired activation of protein synthesis), and there is currently no remedy. Dietary interventions have the potential to boost muscle mass and may benefit individuals who would otherwise be non-responsive to a training stimulus.
Cardiovascular disease and sepsis are two of the biggest public health problems in North America. Increasing evidence further suggests they are linked. Recent studies in human healthy volunteers and in chronic heart failure patients have highlighted the apelin system as a potential target for drug development. We therefore propose to fully validate pre-clinically the potential of apelin as a new target for cardiovascular disease and septic shock.